Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Development and characterization of a bladder cancer xenograft model using patient-derived tumor tissue.

Park B, Jeong BC, Choi YL, Kwon GY, Lim JE, Seo SI, Jeon SS, Lee HM, Choi HY, Lee KS.

Cancer Sci. 2013 May;104(5):631-8. doi: 10.1111/cas.12123. Epub 2013 Mar 24.

2.

Colorectal cancer patient-derived xenografted tumors maintain characteristic features of the original tumors.

Cho YB, Hong HK, Choi YL, Oh E, Joo KM, Jin J, Nam DH, Ko YH, Lee WY.

J Surg Res. 2014 Apr;187(2):502-9. doi: 10.1016/j.jss.2013.11.010. Epub 2013 Nov 15.

PMID:
24332554
3.

Orthotopic transplantation models of pancreatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity.

Loukopoulos P, Kanetaka K, Takamura M, Shibata T, Sakamoto M, Hirohashi S.

Pancreas. 2004 Oct;29(3):193-203.

PMID:
15367885
4.

Establishment and characterization of human urothelial cancer xenografts in severe combined immunodeficient mice.

Abe T, Tada M, Shinohara N, Okada F, Itoh T, Hamada J, Harabayashi T, Chen Q, Moriuchi T, Nonomura K.

Int J Urol. 2006 Jan;13(1):47-57.

5.

Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.

Schulten HJ, Al-Maghrabi J, Al-Ghamdi K, Salama S, Al-Muhayawi S, Chaudhary A, Hamour O, Abuzenadah A, Gari M, Al-Qahtani M.

Anticancer Res. 2011 Dec;31(12):4179-83.

PMID:
22199277
6.

Bladder cancer xenografts: a model of tumor cell heterogeneity.

Russell PJ, Raghavan D, Gregory P, Philips J, Wills EJ, Jelbart M, Wass J, Zbroja RA, Vincent PC.

Cancer Res. 1986 Apr;46(4 Pt 2):2035-40.

7.

Genetic and immunophenotype analyses of TP53 in bladder cancer: TP53 alterations are associated with tumor progression.

Erill N, Colomer A, Verdú M, Román R, Condom E, Hannaoui N, Banús JM, Cordon-Cardo C, Puig X.

Diagn Mol Pathol. 2004 Dec;13(4):217-23.

PMID:
15538112
8.

[Establishment and its biological characteristics of patient-derived lung cancer xenograft models].

Zhuo Y, Wu Y, Guo A, Chen S, Su J.

Zhongguo Fei Ai Za Zhi. 2010 Jun;13(6):568-74. doi: 10.3779/j.issn.1009-3419.2010.06.020. Chinese.

9.

Development of a rapid and practical mutation screening assay for human lung adenocarcinoma.

Choi H, Kratz J, Pham P, Lee S, Ray R, Kwon YW, Mao JH, Kang HC, Jablons D, Kim IJ.

Int J Oncol. 2012 Jun;40(6):1900-6. doi: 10.3892/ijo.2012.1396. Epub 2012 Mar 7.

PMID:
22407457
10.
11.

Patient-derived bladder cancer xenografts in the preclinical development of novel targeted therapies.

Jäger W, Xue H, Hayashi T, Janssen C, Awrey S, Wyatt AW, Anderson S, Moskalev I, Haegert A, Alshalalfa M, Erho N, Davicioni E, Fazli L, Li E, Collins C, Wang Y, Black PC.

Oncotarget. 2015 Aug 28;6(25):21522-32.

12.

Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes.

Cutz JC, Guan J, Bayani J, Yoshimoto M, Xue H, Sutcliffe M, English J, Flint J, LeRiche J, Yee J, Squire JA, Gout PW, Lam S, Wang YZ.

Clin Cancer Res. 2006 Jul 1;12(13):4043-54.

13.

Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models.

Bergamaschi A, Hjortland GO, Triulzi T, Sørlie T, Johnsen H, Ree AH, Russnes HG, Tronnes S, Maelandsmo GM, Fodstad O, Borresen-Dale AL, Engebraaten O.

Mol Oncol. 2009 Dec;3(5-6):469-82. doi: 10.1016/j.molonc.2009.07.003. Epub 2009 Aug 4.

14.

The use of laser scanning cytometry to assess depth of penetration of adenovirus p53 gene therapy in human xenograft biopsies.

Grace MJ, Xie L, Musco ML, Cui S, Gurnani M, DiGiacomo R, Chang A, Indelicato S, Syed J, Johnson R, Nielsen LL.

Am J Pathol. 1999 Dec;155(6):1869-78.

15.

Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.

Fichtner I, Rolff J, Soong R, Hoffmann J, Hammer S, Sommer A, Becker M, Merk J.

Clin Cancer Res. 2008 Oct 15;14(20):6456-68. doi: 10.1158/1078-0432.CCR-08-0138.

16.

Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.

Quiros RM, Ding HG, Gattuso P, Prinz RA, Xu X.

Cancer. 2005 Jun 1;103(11):2261-8. Review.

17.

Analysis of p53, K-ras-2, and C-raf-1 in pulmonary neuroendocrine tumors. Correlation with histological subtype and clinical outcome.

Przygodzki RM, Finkelstein SD, Langer JC, Swalsky PA, Fishback N, Bakker A, Guinee DG, Koss M, Travis WD.

Am J Pathol. 1996 May;148(5):1531-41.

18.

Cytogenetic analysis of multifocal bladder cancer supports a monoclonal origin and intraepithelial spread of tumor cells.

Simon R, Eltze E, Schäfer KL, Bürger H, Semjonow A, Hertle L, Dockhorn-Dworniczak B, Terpe HJ, Böcker W.

Cancer Res. 2001 Jan 1;61(1):355-62.

19.

Assessment of a novel VEGF targeted agent using patient-derived tumor tissue xenograft models of colon carcinoma with lymphatic and hepatic metastases.

Jin K, Li G, Cui B, Zhang J, Lan H, Han N, Xie B, Cao F, He K, Wang H, Xu Z, Teng L, Zhu T.

PLoS One. 2011;6(12):e28384. doi: 10.1371/journal.pone.0028384. Epub 2011 Dec 2.

20.

Alterations of beta- and gamma-catenin in N-butyl-N-(-4-hydroxybutyl)nitrosamine-induced murine bladder cancer.

Shiina H, Igawa M, Urakami S, Shigeno K, Yoneda T, Terashima M, Deguchi M, Ribeiro-Filho L, Dahiya R.

Cancer Res. 2001 Oct 1;61(19):7101-9.

Supplemental Content

Support Center